Business, energy, technology, markets and global industry news from Business News Today

TrumpRx.gov

PharmaDeviceNews TrumpRx.gov
Representative image depicting Amgen’s discounted pricing for Aimovig and Amjevita under the TrumpRx.gov platform, reflecting a broader shift in U.S. drug cost strategy and policy alignment.
Pharma & Biotech

Amgen adds Aimovig and Amjevita to TrumpRx platform in latest move to defuse U.S. pricing pressure

Amgen has expanded its direct-to-patient program, AmgenNow, to include Aimovig (erenumab-aooe) and Amjevita (adalimumab-atto), each now available at a flat monthly price of $299 for eligible U.S. patients. This development forms part of Amgen’s broader agreement with the Trump Administration, satisfying conditions laid out in the President’s July 31 policy letter and positioning the company

Read More
Representative image illustrating Boehringer Ingelheim’s $10B U.S. expansion and participation in TrumpRx.gov, highlighting the intersection of pharmaceutical manufacturing, direct drug pricing, and U.S. government policy.
Pharma & Biotech

Why Boehringer’s $10bn U.S. investment and TrumpRx deal may reshape pharma cost dynamics

Boehringer Ingelheim’s $10B U.S. investment and TrumpRx.gov deal may redefine drug pricing and supply chains. Find out what this changes for pharma now.

Read More